These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 27816107)
21. Pharmacological chaperoning: a primer on mechanism and pharmacology. Leidenheimer NJ; Ryder KG Pharmacol Res; 2014 May; 83():10-9. PubMed ID: 24530489 [TBL] [Abstract][Full Text] [Related]
22. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Fan JQ Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864 [TBL] [Abstract][Full Text] [Related]
23. LAMP2 as a marker of EBV-mediated B lymphocyte transformation in the study of lysosomal storage diseases. Mello AS; Goldim MP; Mezzalira J; Garcia CS; Daitx VV; Castilhos CD; Viegas MS; Vieira OV; Coelho JC Mol Cell Biochem; 2014 Jan; 385(1-2):1-6. PubMed ID: 24068328 [TBL] [Abstract][Full Text] [Related]
28. Neurodegenerative lysosomal disorders: a continuum from development to late age. Nixon RA; Yang DS; Lee JH Autophagy; 2008 Jul; 4(5):590-9. PubMed ID: 18497567 [TBL] [Abstract][Full Text] [Related]
29. Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function. Pisonero-Vaquero S; Medina DL Curr Drug Metab; 2017; 18(12):1147-1158. PubMed ID: 28952432 [TBL] [Abstract][Full Text] [Related]
31. Using pharmacological chaperones to restore proteostasis. Wang YJ; Di XJ; Mu TW Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662 [TBL] [Abstract][Full Text] [Related]
32. Pathogenic cascades in lysosomal disease-Why so complex? Walkley SU J Inherit Metab Dis; 2009 Apr; 32(2):181-9. PubMed ID: 19130290 [TBL] [Abstract][Full Text] [Related]
33. Newborn screening for lysosomal storage disorders. Nakamura K; Hattori K; Endo F Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327 [TBL] [Abstract][Full Text] [Related]
34. From bedside to cell biology: a century of history on lysosomal dysfunction. Coutinho MF; Matos L; Alves S Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857 [TBL] [Abstract][Full Text] [Related]
35. Sugar-mimicking glycosidase inhibitors: bioactivity and application. Asano N Cell Mol Life Sci; 2009 May; 66(9):1479-92. PubMed ID: 19132292 [TBL] [Abstract][Full Text] [Related]
36. "Three sources and three component parts" of free oligosaccharides. Pismenetskaya IU; Butters TD Ukr Biochem J; 2014; 86(6):5-17. PubMed ID: 25816601 [TBL] [Abstract][Full Text] [Related]
37. Biosynthesis of lysosomal proteinases in health and disease. Mach L Biol Chem; 2002 May; 383(5):751-6. PubMed ID: 12108539 [TBL] [Abstract][Full Text] [Related]
39. Impairment of homeostasis in lysosomal storage disorders. Segatori L IUBMB Life; 2014 Jul; 66(7):472-7. PubMed ID: 25044960 [TBL] [Abstract][Full Text] [Related]
40. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases. Oh DB BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]